首页> 外文期刊>ClinicoEconomics and Outcomes Research >Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
【24h】

Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States

机译:在美国,接受过实体瘤治疗的部分高危门诊患者发生静脉血栓栓塞的医疗保健费用

获取原文
           

摘要

Background: This study examines venous thromboembolism (VTE)-associated resource utilization and real-world costs in ambulatory patients initiating chemotherapy for selected common high-risk solid tumors. Methods: Health care claims data (2004–2009) from the IMS/PharMetrics? Patient-Centric database were collected for propensity score-matched adult cancer (lung, colorectal, pancreatic, gastric, bladder, or ovarian) patients initiating chemotherapy with VTE (n = 912) and without VTE (n = 2736). Health care resource utilization (inpatient, outpatient, and outpatient prescription drug claims) and costs were compared between the two cohorts during the 12-month follow-up period after the index VTE event. Incremental costs were adjusted for demographic and clinical covariates. Results: Cancer patients with VTE had approximately three times as many all-cause hospitalizations (mean 1.38 versus 0.55 per patient) and days in hospital (10.19 versus 3.37), and more outpatient claims (331 versus 206) than cancer patients without VTE (all P < 0.0001). Cancer patients with VTE incurred higher overall all-cause inpatient costs (mean USD 21,299 versus USD 7459 per patient), outpatient costs (USD 53,660 versus USD 34,232 per patient), and total health care costs (USD 74,959 versus USD 41,691 per patient) than cancer patients without VTE (all P < 0.0001). Total mean VTE-related health care costs were USD 9247 per patient over 12 months. Adjusted mean incremental all-cause health care costs of VTE were USD 30,538 per patient for cancer overall, ranging from USD 11,946 for gastric to USD 38,983 for pancreatic cancer. Conclusion: VTE is associated with significant inpatient and outpatient resource utilization, and increased all-cause (in addition to VTE-related) health care costs among ambulatory cancer patients. Measures to prevent outpatient cancer-associated VTE may reduce health care utilization and costs in this population.
机译:背景:本研究检查了针对选择的常见高危实体瘤开始化疗的非卧床患者的静脉血栓栓塞(VTE)相关资源利用和实际费用。方法:从IMS / PharMetrics 患者中心数据库中收集倾向得分匹配的成年癌症(肺癌,大肠癌,胰腺癌,胰腺癌,胃癌,膀胱癌或卵巢癌)的医疗索赔数据(2004-2009年) )开始接受VTE(n = 912)而未接受VTE(n = 2736)化疗的患者。在指数VTE事件发生后的12个月随访期内,比较了两个队列之间的医疗资源利用率(住院,门诊和门诊处方药索赔)和费用。根据人口统计和临床协变量调整了增量成本。结果:患有VTE的癌症患者住院的全因住院次数(分别为1.38 vs 0.55每名患者)和三天(10.19 vs 3.37)是无VTE癌症患者(所有患者)的三倍多(门诊索赔)(331 vs 206) P <0.0001)。患有VTE的癌症患者的全因住院总费用(平均每位患者21,299美元对7459美元),门诊费用(每位患者53,660美元对34,232美元)以及医疗总费用(每位患者74,959美元对41,691美元)更高没有VTE的癌症患者(所有P <0.0001)。在12个月内,每位患者与VTE相关的平均医疗保健总费用为9247美元。调整后的VTE平均因癌症引起的全因医疗保健费用平均为每位患者30,538美元,范围从胃癌的11,946美元到胰腺癌的38,983美元。结论:VTE与住院和门诊患者资源的大量利用有关,并增加了非门诊癌症患者全因(除了与VTE相关的)医疗费用。预防门诊与癌症相关的VTE的措施可能会降低该人群的医疗保健利用率和成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号